Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.50 |
| ▸ | CHKA | P35790 | 6/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190176 | 1.00 | AHCY (0.50) | AHCYCHKAEZH2NEK2ADORA2A | |
| SCHEMBL19820687 | 1.00 | AHCY (0.50) | AHCYCHKAEZH2NEK2ADORA2A | |
| SCHEMBL19714827 | 0.92 | ADCY5 (0.49) | AHCYCHKAEZH2NEK2ADORA2A | |
| SCHEMBL19820529 | 0.85 | CHKA (0.48) | AHCYCHKAEZH2ADORA2AADCY5 | |
| SCHEMBL21190302 | 0.85 | CHKA (0.48) | AHCYCHKAEZH2ADORA2AADCY5 | |
| SCHEMBL19714830 | 0.82 | ADCY5 (0.67) | AHCYCHKAEZH2ADCY5 | |
| SCHEMBL19714860 | 0.81 | ADCY5 (0.48) | AHCYCHKAEZH2ADCY5 | |
| SCHEMBL19820530 | 0.81 | AHCY (0.51) | AHCYEZH2ADORA2A | |
| SCHEMBL21176115 | 0.77 | CHKA (0.68) | CHKA | |
| SCHEMBL19820779 | 0.77 | CHKA (0.68) | CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | disclosed |